BA
NKTR icon

BlackRock Advisors’s Nektar Therapeutics NKTR Stock Holding History

BlackRock Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.02M Buy
10,972
+6,393
+140% +$1.3M ﹤0.01% 1504
2016
Q3 		$1.18M Sell
4,579
-32,924
-88% -$8.48M ﹤0.01% 1738
2016
Q2 		$8.01M Sell
37,503
-118,053
-76% -$26.4M 0.01% 919
2016
Q1 		$32.1M Sell
155,556
-589
-0.4% -$113K 0.03% 414
2015
Q4 		$39.5M Buy
156,145
+3,006
+2% +$618K 0.04% 365
2015
Q3 		$25.2M Buy
153,139
+65,790
+75% +$11.6M 0.03% 464
2015
Q2 		$16.4M Buy
87,349
+81,932
+1,512% +$14.1M 0.02% 599
2015
Q1 		$894K Buy
5,417
+796
+17% +$164K ﹤0.01% 1634
2014
Q4 		$1.07M Sell
4,621
-213
-4% -$45.5K ﹤0.01% 1449
2014
Q3 		$875K Sell
4,834
-92
-2% -$17.6K ﹤0.01% 1520
2014
Q2 		$947K Sell
4,926
-8,726
-64% -$1.54M ﹤0.01% 1538
2014
Q1 		$2.48M Buy
13,652
+8,652
+173% +$1.71M ﹤0.01% 1127
2013
Q4 		$851K Buy
5,000
+364
+8% +$58.7K ﹤0.01% 1621
2013
Q3 		$726K Buy
4,636
+11
+0.2% +$2.03K ﹤0.01% 1636
2013
Q2 		$801K Buy
+4,625
New +$709K ﹤0.01% 1499

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Advisors's NKTR Position: Q4 2016 in Review

BlackRock Advisors increased its Nektar Therapeutics (NKTR) stake by 140% in Q4 2016, buying an estimated $1.3M and bringing the position to 10,972 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1504.

BlackRock Advisors first reported a position in NKTR in Q2 2013 and has held it in 15 quarters since. The position peaked at $39.5M in Q4 2015. 199 funds tracked by Wall St. Rank hold NKTR as of Q4 2016.

  • BlackRock Advisors held 10,972 shares of Nektar Therapeutics worth $2.02M as of Q4 2016.
  • BlackRock Advisors bought 6,393 Nektar Therapeutics shares in Q4 2016, an estimated $1.3M.
  • Nektar Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1504 holding.
  • BlackRock Advisors first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Nektar Therapeutics position peaked at $39.5M in Q4 2015.
  • 199 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.